Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peng Chen
Observed name:
P. Chen
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Jiangsu Cancer Hospital,
Tianjin Medical University,
Nanjing Medical University
ORCID:
0009-0007-2417-5824
Observed ORCID:
0009-0007-2417-5824
OpenAlex ID:
A5133549669
5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma
2025
·
Yuanying Feng
, Yuchao He
, et al.
·
EMBO Molecular Medicine
·
10
PDF
Cell-free DNA assay for malignancy classification of high-risk lung nodules
2024
·
Siwei Wang
, Fanchen Meng
, et al.
·
Journal of Thoracic and Cardiovascular Surgery
·
5
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.
2026
·
Caicun Zhou
, Anwen Xiong
, et al.
·
Journal of Clinical Oncology
·
4
DZD6008, a fourth-generation EGFR TKI, in pretreated NSCLC patients with EGFR C797X mutations: Results from phase 1/2 studies.
2026
·
Mengzhao Wang
, Elaine Shum
, et al.
·
Journal of Clinical Oncology
·
2
Taletrectinib in ROS1+ non–small cell lung cancer: a cost-effectiveness analysis in the United States
2026
·
Gengwei Huo
, Xiaoyan Wang
, et al.
·
Frontiers in Pharmacology
·
2
PDF
LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY
2026
·
B. Besse
, E. Felip
, et al.
·
ESMO Open
·
2
PDF
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC
2026
·
Gengwei Huo
, Peng Chen
·
Expert Review of Anticancer Therapy
·
2
Chemotherapy-induced peripheral neuropathy associated with docetaxel or nab-paclitaxel among patients with lung cancer: a prospective dual-center cohort study
2026
·
Yalan Liu
, Yurong Li
, et al.
·
Frontiers in Pharmacology
·
1
PDF
SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study.
2026
·
Yi Hu
, Haitao Tao
, et al.
·
Journal of Clinical Oncology
·
1
SHR-1826, a c-MET directed antibody-drug conjugate (ADC), in advanced solid tumors: Updates from a phase 1 study.
2026
·
Longhua Sun
, Jinhua Wen
, et al.
·
Journal of Clinical Oncology
·
1
Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study
2026
·
Zhanhong Xie
, Qiming Wang
, et al.
·
Cancer Research
·
1
Ivonescimab Plus Chemotherapy versus Bevacizumab Plus Chemotherapy in EGFR-Mutant Lung Adenocarcinoma After EGFR-TKI Failure: A Two-Center Retrospective Real-World Propensity Score-Matched Study
2026
·
Jianxi Zhou
, Yinghao Wang
, et al.
·
Drug Design Development and Therapy
Glucocorticoid and mitophagy signaling–based molecular subtyping reveals HMGA1 as a prognostic and immunotherapy biomarker in lung adenocarcinoma
2026
·
Junjie Yu
, Yantao Jiang
, et al.
·
npj Precision Oncology
PDF
WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human Study
2026
·
Shun Lu
, Xinghao Ai
, et al.
·
Research Square
PDF
Unveiling molecular incomplete response (mIR) via ultra-deep NGS: a novel concept contrasting pathologic complete response (pCR) in occult lymph node micrometastases of non-small cell lung cancer
2026
·
Meng Lu
, Ran Zhang
, et al.
·
Cancer Biology and Medicine
PDF
cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment
2026
·
Ran Zuo
, Yuchao He
, et al.
·
Communications Biology
PDF
Safety and efficacy of APS03118, a next-generation RET inhibitor, in patients with non-small cell lung cancer (NSCLC): Results from a phase I clinical trial.
2026
·
Shun Lu
, Zhen Zhou
, et al.
·
Journal of Clinical Oncology
Distinct multiplex immunofluorescence-based immune and stromal marker expression profile of subcutaneously metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report
2026
·
Hongmin Li
, Ying Liang
, et al.
·
Translational Lung Cancer Research
Comprehensive Pan-Cancer Study Identifies Hepatic Leukemia Factor as a Crucial Biomarker for Immunity and Prognostic Accuracy
2026
·
Kang Wen
, Gulijiayina Nuerhashi
, et al.
·
Research Square
PDF
WITHDRAWN: GFH375 in Patients with Previously Treated Non-Small Cell Lung Cancer and KRASG12D Mutations: A First-in-Human Study
2026
·
Shun Lu
, Xinghao Ai
, et al.
·
Research Square
9MO A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer
2026
·
Li Zhang
, Y. Ma
, et al.
·
ESMO Open
929MO Becotatug (JMT101, Beco) combined with docetaxel (albumin-bound, HB1801) for the treatment of patients (pts) with locally advanced squamous cell non-small cell lung cancer (sqNSCLC): A randomized control phase II study (BATTLE study)
2025
·
L. Zhang
, W.F. Fang
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
22
Citation count:
31
H-index:
3
I10-index:
1
Year
Topic
Type